Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Ways to Fix Starbucks Biggest Challenges

3 Ways to Fix Starbucks Biggest Challenges

2 Things Fed Chairman Jerome Powell Just Said Upset Investors

2 Things Fed Chairman Jerome Powell Just Said Upset Investors

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up